Non-small cell lung cancer nonsquamous · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | ~6.1 mo | ~14.2 mo | ~9 | ~R 45 276 PFS proxy · indirect | 7 |
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | ~5.0 mo | ~10.0 mo | ~4 | ~R 17 056 PFS proxy · indirect | 11 |
Cisplatin and Vinorelbine (CVb) Variant #11 | — | R 4 117 | 42d | — | ~10.0 mo | — | — | 10 |
3 of 3 regimens shown